Via collaborations with national and international hospitals, we are creating one of the largest Biobanks in Spain of pancreatic patient-derived xenografts (PDXs). PDXs are generated by implanting resected tumor pieces into immune compromised mice. The resulting “avatar” mice can serve as preclinical models to assess the effect of CSC inhibitors on PDAC tumor formation.
Using ”avatar” mice, we have discovered therapies that could be potentially useful and effective for treating PDAC.
